Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical Treatment

Abstract Introduction Omaveloxolone, the only approved medication for Friedreich ataxia (FRDA), is an NRF2 activator available since July 2023. We examined safety monitoring of omaveloxolone administration over the first 12 months of administration. Methods We recorded baseline and follow-up serum t...

詳細記述

書誌詳細

主要な著者:	Katherine Gunther, Victoria Profeta, Medina Keita, Courtney Park, McKenzie Wells, Sonal Sharma, Kimberly Schadt, David R. Lynch
フォーマット:	Artigo
言語:	Inglês
出版事項:	Adis, Springer Healthcare 2025-04-01
シリーズ:	Neurology and Therapy
主題:	Brain natriuretic peptide Mitochondria transaminase Movement disorder Omaveloxolone
オンライン･アクセス:	https://doi.org/10.1007/s40120-025-00749-3
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!